Marie‐Line Garcia‐Larnicol

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study

Thierry André, David Tougeron, Guillaume Piessen et al. · Journal of Clinical Oncology · 2022 · 345 citations · Full text

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study

Romain Cohen, Jaafar Bennouna, Aurélia Meurisse et al. · Journal for ImmunoTherapy of Cancer · 2020 · 77 citations · Full text

[Use of complementary medicine by cancer patients in a French oncology department].

S. Trager-Maury, Christophe Tournigand, Frédérique Maindrault‐Gœbel et al. · PubMed · 2007 · 58 citations

Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study.

Thierry André, David Tougeron, Guillaume Piessen et al. · Journal of Clinical Oncology · 2022 · 51 citations

Surgical Oncology, Cancer Management, Immunology +16

Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial

Alice Boilève, Marc Hilmi, Paul Gougis et al. · European Journal of Cancer · 2020 · 40 citations

Phase Ii Trial, Gastrointestinal Oncology, Medicine +10